重组人脑利钠肽治疗I型心肾综合征的临床疗效研究  

Clinical efficacy of recombinant human brain natriuretic peptide in the treatment of type I cardiorenal syndrome

作　　者：沈琦博 梁佳佳 徐燕 SHEN Qibo;LIANG Jiajia;XU Yan(Department of Cardiology,Affiliated Qidong Hospital of Nantong University/Qidong People's Hospital/Qidong Liver Cancer Institute,Nantong 226200,China)

机构地区：[1]南通大学附属启东医院/启东市人民医院/启东肝癌防治研究所心血管内科,226200 [2]常州市中医医院心脏彩超室

出　　处：《心肺血管病杂志》2025年第3期265-270,共6页Journal of Cardiovascular and Pulmonary Diseases

基　　金：南通市卫生健康委员会青年科研项目(QB2021047)。

摘　　要：目的:探讨重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)治疗I型心肾综合征患者的临床疗效。方法:纳入2022年1月1日至2024年6月30日,在启东市人民医院心血管内科收治的I型心肾综合征患者192例,随机分为两组,对照组96例接受常规抗心力衰竭药物联合小剂量多巴胺治疗,干预组96例在对照组治疗基础上加用rhBNP治疗,分析并比较两组患者的基线资料、心肾功能相关指标、hs-CRP、糖类抗原125(carbohydrate antigen 125,CA125)、住院总费用、住院总天数、3个月内再住院率及药物不良反应等。结果:治疗后两组患者血清NT-proBNP、HR、LVEDD、BUN、Scr、hs-CRP、CA125均较治疗前显著减低(P<0.05),LVEF、eGFR、日净出量均较治疗前显著升高(P<0.05),治疗后干预组上述指标(除LVEDD)改善情况均显著优于对照组(P<0.05),干预组住院天数及3个月内再住院率显著低于对照组(P<0.05),两组住院总费用比较,差异无统计学意义(P>0.05),干预组不良反应发生率7.3%,对照组不良反应发生率8.3%,两组患者总的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:rhBNP对I型心肾综合征患者疗效显著,其与小剂量多巴胺联用对I型心肾综合征治疗效果要优于传统小剂量多巴胺,能显著改善患者的心肾功能,且能减少住院天数及再住院率,具有临床推广应用价值。Objective:To explore the clinical efficacy of recombinant human brain natriuretic peptide(rhBNP)in the treatment of patients with type I cardiorenal syndrome.Methods:A total of 192 patients with type I cardiorenal syndrome admitted to the Cardiovascular Department of Qidong People's Hospital from January 1,2022 to June 30,2024 were randomly divided into two groups.The control group consisted of 96 patients who received conventional anti heart failure drugs combined with low-dose dopamine treatment,while the intervention group consisted of 96 patients who received rhBNP treatment in addition to the control group treatment.Baseline data,cardiovascular and renal function related indicators,hs-CRP,carbohydrate antigen 125(CA125),the total hospitalization expenses,total length of hospital stay,readmission rate within 3 months,and adverse drug reactions were analyzed and compared between the two groups.Results:After treatment,the serum NT proBNP,HR,LVEDD,blood urea nitrogen(BUN),Scr,hs CRP,and CA125 in both groups of patients were significantly reduced compared to before treatment(P<0.05).The LVEF,eGFR,and daily net output were significantly increased compared to before treatment(P<0.05).The improvement of the above indicators(except LVEDD)in the intervention group after treatment was significantly better than that in the control group(P<0.05).Compared with the control group,the length of hospital stay and readmission rate within 3 months in the intervention group were obviously reduced(P<0.05).The total hospitalization expenses between the two groups showed no significant difference(P>0.05).The incidence of adverse reactions in the intervention group was 7.3%,while the incidence of adverse reactions in the control group was 8.3%.There was no significant difference in the total incidence rate of adverse reactions between the two groups of patients(P>0.05).Conclusions:rhBNP has a significant effect on patients with type I cardiorenal syndrome,and its combination with low-dose dopamine is better than that of traditional

关 键 词：重组人脑利钠肽 小剂量多巴胺 急性心力衰竭 I型心肾综合征 

分 类 号：R54[医药卫生—心血管疾病]